Scarica l'app Stockscreener
1.62
0.62%
0.01
Dopo l'orario di chiusura:
1.60
-0.02
-1.23%
Precedente Chiudi:
$1.61
Aprire:
$1.61
Volume 24 ore:
725.92K
Relative Volume:
0.46
Capitalizzazione di mercato:
$51.12M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.5827
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
+4.52%
1M Prestazione:
-0.61%
6M Prestazione:
+6.58%
1 anno Prestazione:
-68.05%
Intervallo 1D:
$1.57
$1.64
Intervallo di 1 settimana:
$1.52
$1.70
Portata 52W:
$1.05
$5.6509
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.62 | 51.12M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics shares slide sharply following mixed oncology trial update - MSN
Gains Report: What is Acrivon Therapeutics Incs 5 year growth outlookWeekly Risk Summary & Real-Time Volume Analysis - baoquankhu1.vn
Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha
Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026Slideshow - Seeking Alpha
Acrivon Therapeutics Highlights ACR-368’s ~50% Response in Serous Endometrial Cancer at TD Cowen Conf. - Defense World
Acrivon Therapeutics (ACRV) CAO awarded 31,900 stock options at $0.00 strike - Stock Titan
Acrivon Therapeutics (ACRV) CMO granted stock options on 174,068 shares - Stock Titan
Executive Mary Miller at Acrivon Therapeutics (ACRV) granted 129,760 options - Stock Titan
Acrivon Therapeutics (ACRV) CDO awarded option on 94,946 shares - Stock Titan
Acrivon Therapeutics (ACRV) COO receives 186,728 stock options vesting from 2027 - Stock Titan
Acrivon Therapeutics (ACRV) grants stock options to CEO and EVP - Stock Titan
ACRV Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Acrivon Therapeutics, Inc. (ACRV) Raised to Buy: Discover the Reasons - Bitget
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why - Yahoo Finance
Acrivon Therapeutics (ACRV) CFO granted 132,925 stock options in new award - Stock Titan
Jefferies reiterates Acrivon Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Jefferies reiterates Acrivon Therapeutics stock rating on trial data - Investing.com
Acrivon Therapeutics (NASDAQ: ACRV) takes full control of ACR-368 OncoSignature - Stock Titan
What is HC Wainwright’s Estimate for ACRV FY2030 Earnings? - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - Defense World
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Acrivon Therapeutics hosts webcast on ACR-368 trial at ESGO Congress - Investing.com Canada
ACR-368 in Serous Endometrial Cancer: Strong Phase 2b Efficacy, Manageable Safety, and a Clear Accelerated Approval Path Support Buy Rating on Acrivon - TipRanks
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer - MarketBeat
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data - TipRanks
Acrivon (NASDAQ: ACRV) shows ACR-368 activity in endometrial cancer - Stock Titan
ACRV: ACR-368 shows strong efficacy and safety in biomarker-selected endometrial cancer, especially serous cases - TradingView
Pullback Watch: Can Acrivon Therapeutics Inc expand into new marketsRate Hike & Reliable Breakout Forecasts - baoquankhu1.vn
Acrivon Therapeutics (ACRV) insiders detail RSU tax-related share withholding - Stock Titan
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 - GlobeNewswire
Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress - Bitget
Why Acrivon Therapeutics Inc. stock is considered a top pickMarket Growth Report & Risk Managed Investment Strategies - mfd.ru
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen - Defense World
ACRV Stock Price, Forecast & Analysis | ACRIVON THERAPEUTICS INC (NASDAQ:ACRV) - ChartMill
Market Review: Is Acrivon Therapeutics Inc showing insider buyingPrice Action & Verified Momentum Watchlists - baoquankhu1.vn
[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity - Stock Titan
ACRVAcrivon Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory - The Manila Times
Acrivon Therapeutics Strengthens its Precision Medicine - GlobeNewswire
Inside Acrivon's new lab built to speed up precision medicines - Stock Titan
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Trading Recap: What is Acrivon Therapeutics Incs 5 year growth outlookRecession Risk & Stock Portfolio Risk Management - baoquankhu1.vn
ACRV Should I Buy - Intellectia AI
Can Acrivon Therapeutics Inc. expand into new marketsQuarterly Risk Review & Risk Controlled Stock Alerts - mfd.ru
Reviewing Acrivon Therapeutics (NASDAQ:ACRV) & Innate Pharma (OTCMKTS:IPHYF) - Defense World
Why Acrivon Therapeutics Inc. stock is a value investor pickWeekly Risk Summary & AI Powered Buy/Sell Recommendations - mfd.ru
Trade Recap: Is Acrivon Therapeutics Inc showing insider buying2025 Sector Review & Smart Swing Trading Alerts - baoquankhu1.vn
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):